HOOKIPA Pharma
HOOK
Market cap $41.3M

4.17 USD

+0.27

6.92%

At close Oct 17, 4:00 PM EDT

1 day

6.92%

5 days

9.74%

1 month

-12.76%

3 months

-35.75%

6 months

-45.35%

Year to date

-49.76%

1 year

-20.27%

5 years

-95.02%

About: HOOKIPA Pharma Inc is a clinical stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. It uses off-the-shelf technologies, VaxWave and TheraT, to elicit directly within patients a response of antigen-specific killer T cells and antibodies.

Employees: 124

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,740 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

129% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 7

123% more call options, than puts

Call options by funds: $89K | Put options by funds: $40K

9.0% less ownership

Funds ownership: 45.5% [Q1] → 36.51% (-9.0%) [Q2]

13% less funds holding

Funds holding: 47 [Q1] → 41 (-6) [Q2]

21% less capital invested

Capital invested by funds: $26.4M [Q1] → $20.9M (-$5.57M) [Q2]

46% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 13

100% less funds holding in top 10

Funds holding in top 10: 1 [Q1] → 0 (-1) [Q2]

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$23

452%

upside

Avg. target

$24

464%

upside

High target

$24

476%

upside

2 analyst ratings

2 positive

100%

0 neutral

0%

0 negative

0%

JMP Securities Roy Buchanan 26% 1-year accuracy 5 / 19 met price target	476%upside $24	Market Outperform Maintained	9 Aug 2024
JMP Securities Jason Butler 50% 1-year accuracy 20 / 40 met price target	452%upside $23	Market Outperform Maintained	26 Jul 2024

See Analyst Rankings

Financial journalist opinion

HOOKIPA Pharma to Present Strong Preclinical HB-700 Dataset

Preclinical proof-of-concept package to be presented at Industry Summit on RAS being held September 24-26, 2024 Preclinical proof-of-concept package to be presented at Industry Summit on RAS being held September 24-26, 2024

HOOKIPA Pharma to Present Strong Preclinical HB-700 Dataset

Kaskela Law LLC Announces Shareholder Investigation of HOOKIPA Pharma Inc. (NASDAQ: HOOK) and Encourages Investors to Contact the Firm

PHILADELPHIA--(BUSINESS WIRE)--Kaskela Law LLC announces that it is investigating HOOKIPA Pharma Inc. (NASDAQ: HOOK) on behalf of the company's shareholders. Since May 2024, shares of HOOKIPA's stock have declined from a trading price of over $10.00 per share to a current trading price of less than $5.00 per share, a cumulative decline of over 50% in value. The investigation seeks to determine whether HOOKIPA and/or the company's officers and directors violated the securities laws or breached t.

Kaskela Law LLC Announces Shareholder Investigation of HOOKIPA Pharma Inc. (NASDAQ: HOOK) and Encourages Investors to Contact the Firm

Zacks Investment Research

Wall Street Analysts Think HOOKIPA Pharma (HOOK) Could Surge 622.75%: Read This Before Placing a Bet

The mean of analysts' price targets for HOOKIPA Pharma (HOOK) points to a 622.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Think HOOKIPA Pharma (HOOK) Could Surge 622.75%: Read This Before Placing a Bet

HOOKIPA Pharma Announces Board of Directors Changes

NEW YORK and VIENNA, Aug. 30, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK) (“HOOKIPA” or the “Company”), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the appointment of Director Julie O'Neill as Non-Executive Chair of the Company's Board of Directors. She succeeds Jan van de Winkel, who has decided to step down from the Board effective August 30, 2024, due to increasing time commitments from his executive position as Chief Executive Officer of Genmab A/S. The Company also announced that Tim Reilly has chosen to step down from the Board, also effective August 30th, to be able to dedicate more time to his other professional responsibilities.

HOOKIPA Pharma Announces Board of Directors Changes

HOOKIPA Pharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

NEW YORK and VIENNA, Aug. 28, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, “HOOKIPA”, the “Company”), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that members of the management team will participate in the H.C. Wainwright 26th Annual Global Investment Conference, taking place from September 9th-11th, 2024 in New York.

HOOKIPA Pharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

HOOKIPA Pharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights

New Leadership Appointments; Positive Clinical and Regulatory Reports for the Lead Product Candidate, HB-200 (eseba-vec); On track to initiate the Phase 2/3 “AVALON-1” study with eseba-vec in Q4 2024

HOOKIPA Pharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Zacks Investment Research

Wall Street Analysts Believe HOOKIPA Pharma (HOOK) Could Rally 634.38%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 634.4% in HOOKIPA Pharma (HOOK). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Believe HOOKIPA Pharma (HOOK) Could Rally 634.38%: Here's is How to Trade

Zacks Investment Research

Will HOOKIPA Pharma Inc. (HOOK) Report Negative Q2 Earnings? What You Should Know

HOOKIPA Pharma (HOOK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will HOOKIPA Pharma Inc. (HOOK) Report Negative Q2 Earnings? What You Should Know

HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200

NEW YORK and VIENNA, July 22, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK) (”HOOKIPA” or the “Company”), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the appointment of Directors Dr. Malte Peters as Chief Executive Officer and Terry Coelho as Executive Vice President and Chief Financial Officer, effective July 22, 2024. They will both retain their positions on the Board of Directors (“Board”).

HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200

HOOKIPA Pharma Announces Effective Date of 1-for-10 Reverse Stock Split

NEW YORK and VIENNA, July 08, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, “HOOKIPA”), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that a 1-for-10 reverse stock split of its outstanding shares of common stock will be effective as of 5:00 p.m. Eastern Time on July 9, 2024.

HOOKIPA Pharma Announces Effective Date of 1-for-10 Reverse Stock Split

See News Rankings

Charts implemented using Lightweight Charts™